Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen specializes in biotechnology as it seeks to advance medical therapeutics. Its strategic focus encompasses diverse ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza ...

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza's ...

Management emphasized its commitment to driving pipeline development, especially in emerging therapeutic areas like oncology and rare diseases. Updates on MariTide, Amgen's weight-reduction ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...